Exonhit and BGI Announce Successful Completion of a Promising Next-Generation Sequencing Project

Combining complementary platforms facilitates rapid and comprehensive discovery and development of biologically relevant markers

29-Jul-2011 - Exonhit and BGI announced the successful completion of a project dedicated to expanding Exonhit’s Genome-Wide SpliceArrayTM to an additional strategic preclinical animal model species.To answer the need for a comprehensive understanding of gene deregulation and the expanding interest in ...

Exonhit Announces Successful Completion of the Second Phase of EHT Dx14 Clinical Validation

EHT Dx14 determinates the exact nature of breast tumors in more than 90% of cases

21-Jul-2011 - Following the first data in benign and malignant fine-needle aspiration (FNA) samples, Exonhit announced successful completion of the second phase of the validation study of EHT Dx14, a new transcriptomic signature allowing to differentiate, at molecular level, benign breast tumors from malignant ...

ExonHit Announces Successful Completion of the First Phase of EHT Dx14 Ongoing Clinical Validation

31-Mar-2011 - ExonHit Therapeutics announced successful completion of the first phase of the validation study of EHT Dx14, a new transcriptomic signature allowing to differentiate, at molecular level, benign breast tumors from malignant ones.“These very promising first results confirm EHT Dx14 capability to ...

Exonhit to Acquire Redpath Integrated Pathology, Inc.

Complementary fit between RedPath’s DNA platform and ExonHit’s RNA platform

27-Apr-2010 - ExonHit Therapeutics S.A. announced that it entered into a binding agreement for the acquisition of RedPath Integrated Pathology, Inc., a privately held molecular diagnostics company, focused on cancer. RedPath will become part of ExonHit’s US operations. Headquartered in Pittsburgh, ...

ExonHit Launches First Product in Alzheimer

07-Dec-2009 - ExonHit Therapeutics announced that AclarusDx™ Alzheimer’s test (formerly known as EHT Dx21), its blood-based test for the detection of Alzheimer’s disease (AD), is now available as a Research Use Only (RUO) product for pharmaceutical companies and academic centers conducting clinical trials in ...

bioMérieux and ExonHit Therapeutics initiate their third diagnostic program

09-Jan-2007 - bioMérieux and ExonHit Therapeutics announced the initiation of their third programme for the screening of cancer from blood. One of the goals is to assist physicians in deciding whether to proceed with surgery for prostate cancer. The collaboration is based on the expertise and intellectual ...

Exonhit files patent on a panel of genes for the diagnosis of Alzheimer's disease from blood

23-May-2006 - ExonHit Therapeutics announced that it has filed a patent with the French Intellectual Property Institute (INPI) which covers a panel of genes that could enable the differential diagnosis of Alzheimer's patients from blood. The use of these genes will allow the identification of patients ...

Exonhit presents new opportunities in blood diagnostics in neurodegenerative diseases

Identification of new markers for BSE in collaboration with Roche Applied Science

06-Dec-2005 - ExonHit Therapeutics announced that the company has identified new blood markers in collaboration with Roche Applied Science for the detection of bovine spongiform encephalopathy (BSE) in living animals. The development of a blood-based BSE test would herald a new era by diagnosing BSE-infected ...